IL327357A - שיטת טיפול משולב בהפרעות אוטואימוניות - Google Patents
שיטת טיפול משולב בהפרעות אוטואימוניותInfo
- Publication number
- IL327357A IL327357A IL327357A IL32735726A IL327357A IL 327357 A IL327357 A IL 327357A IL 327357 A IL327357 A IL 327357A IL 32735726 A IL32735726 A IL 32735726A IL 327357 A IL327357 A IL 327357A
- Authority
- IL
- Israel
- Prior art keywords
- autoimmune disorders
- combination treatment
- autoimmune
- disorders
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363590384P | 2023-10-13 | 2023-10-13 | |
| US202363590431P | 2023-10-14 | 2023-10-14 | |
| US202463620305P | 2024-01-12 | 2024-01-12 | |
| US202463660677P | 2024-06-17 | 2024-06-17 | |
| PCT/US2024/051307 WO2025081174A1 (en) | 2023-10-13 | 2024-10-15 | Combination treatment of autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327357A true IL327357A (he) | 2026-05-01 |
Family
ID=95396609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327357A IL327357A (he) | 2023-10-13 | 2024-10-15 | שיטת טיפול משולב בהפרעות אוטואימוניות |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN122028914A (he) |
| AU (1) | AU2024359636A1 (he) |
| IL (1) | IL327357A (he) |
| WO (1) | WO2025081174A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025219911A1 (en) * | 2024-04-16 | 2025-10-23 | Biohaven Therapeutics Ltd. | Treatment of diseases with monoclonal antibody drugs and molecular degraders |
-
2024
- 2024-10-15 AU AU2024359636A patent/AU2024359636A1/en active Pending
- 2024-10-15 CN CN202480065407.4A patent/CN122028914A/zh active Pending
- 2024-10-15 WO PCT/US2024/051307 patent/WO2025081174A1/en active Pending
- 2024-10-15 IL IL327357A patent/IL327357A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024359636A1 (en) | 2026-05-07 |
| CN122028914A (zh) | 2026-05-12 |
| WO2025081174A1 (en) | 2025-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4525871A4 (en) | TREATMENT OF DEPRESSION | |
| IL315896A (he) | טיפול בתפקוד קוגניטיבי | |
| GB2605422B (en) | Treatment of the central nervous system | |
| IL321560A (he) | טיפול במחלות אוטואימוניות | |
| IL309317A (he) | טיפול במחלות והפרעות הקשורות ל- mtres1 | |
| IL313920A (he) | טיפול בהפרעות לב וריאות | |
| IL315503A (he) | שיטות לטיפול | |
| GB201914034D0 (en) | Treatment of neurological disorders | |
| IL320711A (he) | שיטות טיפול | |
| IL304628A (he) | טיפול בהפרעות עור | |
| IL319571A (he) | R-טריהקסיפנידיל לטיפול בהפרעות תנועה | |
| GB202201824D0 (en) | Methods of treatment | |
| IL321201A (he) | שיטות לטיפול בהפרעות נוירולוגיות | |
| GB202109021D0 (en) | Treatment for autoimmune diseases | |
| CA3308048A1 (en) | Combination treatment of autoimmune disorders | |
| GB202201825D0 (en) | Methods of treatment | |
| GB202201819D0 (en) | Methods of treatment | |
| SMT202500404T1 (it) | Trattamento combinato di compromissione del cervello | |
| IL315890A (he) | טיפול בהפרעות נפשיות | |
| GB202315695D0 (en) | TReatment of cariomyopathy | |
| GB202212506D0 (en) | Treatment of covid-19 | |
| GB202307686D0 (en) | Treatment of conditions | |
| GB202206359D0 (en) | Treatment of pain | |
| GB201908665D0 (en) | Treatment of cognitive disorders | |
| GB202116774D0 (en) | Treatment of pain |